BsAb Manufacturing
With the rapid development of recombinant protein technology, numerous BsAbs have emerged as therapeutic proteins. Creative Biolabs offers three approaches to develop BsAbs for customers: hybrid-hybridoma technology by the somatic fusion of two different hybridoma cell lines; chemical conjugation based on chemical crosslinkers; and genetic methods using recombinant DNA technology.
Home > BsAb Manufacturing
BsAb Manufacturing
Recombinant expression allows for the generation of structurally and functionally defined molecules including IgG-like molecules, appended IgGs, BsAb fragments and bispecific fusion proteins. Moreover, BsAb humanization or fully human BsAbs can be implemented to reduce immunogenicity.
Learn More
Chemical Conjugation is an alternative way to generate BsAbs. This method facilitates chemical coupling of two parental antibodies obtained from recombinant expression or hybridomas. Currently, homobifunctional (such as DTNB and o-PDM) or heterobifunctional (such as SPDP and EDC) cross-linkers are used in the conjugation protocols.
Learn More
BsAb Manufacturing
BsAb Manufacturing
At the early stage of BsAb development, somatic hybridization of two hybridomas were widely used. BsAbs created by hybrid-hybridoma are mainly IgG-like molecules, which generally have longer serum half-lives than bispecific fragments, and maintain Fc-mediated effector functions, including antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cell-mediated cytotoxicity (ADCC), as well as complement-dependent cytotoxicity (CDC).
Learn More
Focus on Bispecific Antibody, Focus on Creative Biolabs

Novel Platforms Facilitate Innovative and Efficient BsAb Development

45-1 Ramsey Road, Shirley, NY 11967, USA 1-631-381-2994 1-631-207-8356
24x7 CUSTOMER SERVICE
Easy access to products and services you need from our library via
powerful searching tools
© 2007 - 2019 Creative-Biolabs All Rights Reserved.
Distributors
To view the contact information for a specific location,
select your country or region: